Cancer Institute A national cancer institute
designated cancer center

Need assistance? Contact the Stanford Cancer Clinical Trials Office at 650-498-7061 or ccto-office@stanford.edu.

Ofrecemos Asistencia en Español.


Search all open clinical trials at Stanford online.

New mobile clinical
trial search app!

iTunes | Google Play


Are you thinking of entering a clinical trial? Learn more here.

Español | 中文 | Pусский


View stories from Cancer Clinical Trial participants at Stanford.

Español | 中文 | Pусский

   

Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

The purpose of this study is to test the safety of OMP-54F28 when combined with the chemotherapy drugs paclitaxel and carboplatin that are standard of care for ovarian cancer. The study is designed to test the safety of OMP-54F28 at different dose levels and the effects, both good and bad, that it has on ovarian cancer when combined with paclitaxel and carboplatin. Since OMP-54F28 has not been tested with paclitaxel and carboplatin in humans before, it is not known if it will provide any benefit and if it will cause harmful side effects.


Stanford Medicine Resources:

Footer Links: